
Last update at 2026-06-18T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -15.30000M | -28.08900M | -28.03300M | -236.17500M | -48.78400M |
| Minority interest | 0.00000M | 0.00100M | 0.00000M | 0.39M | 0.55M |
| Net income | -15.30300M | -28.09100M | -28.03600M | -235.78400M | -48.23700M |
| Selling general administrative | 7.26M | 8.93M | 20.42M | 31.25M | 10.38M |
| Selling and marketing expenses | 8.49M | 11.49M | - | - | - |
| Gross profit | 6.14M | 7.23M | 7.32M | 8.74M | 2.51M |
| Reconciled depreciation | 3.21M | 2.87M | 2.85M | 2.69M | 2.19M |
| Ebit | -15.21600M | -27.92600M | - | -39.85300M | -21.13500M |
| Ebitda | -12.00500M | -25.05330M | -25.08700M | -233.31400M | -45.94500M |
| Depreciation and amortization | 3.21M | 2.87M | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -19.79100M | -33.22100M | -31.77300M | -37.42900M | -20.56900M |
| Other operating expenses | 27.92M | 43.58M | - | - | - |
| Interest expense | 0.08M | 0.10M | 0.10M | 0.17M | 0.65M |
| Tax provision | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00200M |
| Interest income | 6.53M | 6.04M | 2.63M | 0.16M | 0.08M |
| Net interest income | 6.45M | 5.88M | 2.53M | -0.00900M | -0.57100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.00300M | 0.00300M | 0.00300M | 0.00300M | 0.00200M |
| Total revenue | 8.13M | 10.26M | 9.41M | 10.89M | 3.26M |
| Total operating expenses | 25.93M | 40.45M | 41.19M | 48.32M | 23.83M |
| Cost of revenue | 1.99M | 3.03M | 2.10M | 2.15M | 0.75M |
| Total other income expense net | 4.49M | 5.13M | - | - | - |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -15.30300M | -28.09200M | -28.03600M | -236.17800M | -48.78600M |
| Net income applicable to common shares | - | - | -28.03600M | -235.78400M | -48.23700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 175.90M | 195.81M | 221.94M | 252.81M | 39.88M |
| Intangible assets | 7.71M | 8.97M | 5.91M | 7.04M | 8.26M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.22M | 1.10M | 0.00100M | 0.84M | 1.28M |
| Total liab | 6.42M | 10.44M | 8.48M | 10.39M | 162.32M |
| Total stockholder equity | 169.48M | 185.37M | 213.46M | 242.42M | -120.51300M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 5.78M | 7.36M | - | 4.29M | 4.06M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00600M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00600M |
| Retained earnings | -476.57200M | -461.89800M | - | -408.72400M | -172.94000M |
| Other liab | - | - | - | 0.23M | 0.08M |
| Good will | - | - | - | - | - |
| Other assets | - | -0.00628M | 1.81M | 2.42M | 0.48M |
| Cash | 46.47M | 83.56M | 106.76M | 227.21M | 18.79M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 6.42M | 9.16M | 7.42M | 8.96M | 14.23M |
| Current deferred revenue | - | 0.68M | - | - | - |
| Net debt | -46.15500M | -81.20900M | - | - | - |
| Short term debt | 0.32M | 1.13M | - | - | - |
| Short long term debt | 0.02M | 0.02M | 0.03M | 0.01M | 3.73M |
| Short long term debt total | 0.32M | 2.35M | - | - | - |
| Other stockholder equity | 646.04M | 593.59M | - | 59.11M | 52.42M |
| Property plant equipment | - | - | - | 4.64M | 4.46M |
| Total current assets | 151.79M | 172.65M | 202.87M | 238.72M | 26.68M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 207.55M | 235.38M | -128.77100M |
| Short term investments | 92.64M | 72.84M | 81.15M | - | - |
| Net receivables | 7.86M | 9.98M | 8.60M | 6.13M | 3.47M |
| Long term debt | - | - | - | 0.00000M | 0.46M |
| Inventory | 3.60M | 4.71M | 4.30M | 4.19M | 3.05M |
| Accounts payable | 0.25M | 0.40M | 0.32M | 0.40M | 0.36M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | 53.67M | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 92.78M | 0.75M | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 24.11M | 23.15M | 19.08M | 14.09M | 13.20M |
| Capital lease obligations | 0.30M | 2.34M | 1.44M | 1.94M | 1.93M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -25.91000M | 5.49M | -87.56900M | -1.75300M | -1.08900M |
| Change to liabilities | - | - | 0.00000M | -0.12700M | 0.10M |
| Total cashflows from investing activities | -25.91000M | 5.49M | -87.56900M | -1.75300M | -1.08900M |
| Net borrowings | 0.00600M | -0.72000M | - | -3.68100M | -4.62900M |
| Total cash from financing activities | -1.02500M | -1.45900M | - | 241.82M | 32.23M |
| Change to operating activities | - | - | - | 0.53M | 1.94M |
| Net income | -15.30000M | -28.08900M | -28.03600M | -235.78400M | -48.23700M |
| Change in cash | -37.09100M | -23.19200M | -119.09500M | 208.42M | 15.70M |
| Begin period cash flow | 83.56M | 106.76M | 227.21M | 18.79M | 3.08M |
| End period cash flow | 46.47M | 83.56M | 106.76M | 227.21M | 18.79M |
| Total cash from operating activities | -10.00200M | -26.13200M | -30.95400M | -31.49400M | -15.58800M |
| Issuance of capital stock | 0.00000M | 0.06M | 0.12M | 253.90M | 37.63M |
| Depreciation | 3.21M | 2.87M | 2.85M | 2.68M | 2.18M |
| Other cashflows from investing activities | 0.01M | 0.17M | - | - | 0.09M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 1.06M | -0.49200M | -0.10600M | -1.15100M | -1.23400M |
| Change to account receivables | 0.74M | 0.18M | - | -4.96400M | 1.02M |
| Sale purchase of stock | - | - | - | - | 0.00000M |
| Other cashflows from financing activities | -1.03100M | -0.79400M | - | -8.39600M | -0.76600M |
| Change to netincome | - | - | - | 207.31M | 28.64M |
| Capital expenditures | 0.32M | 0.70M | 0.86M | 1.85M | 1.10M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.98M | -0.62100M | -4.67400M | -5.71200M | 1.81M |
| Stock based compensation | 0.24M | 0.56M | 1.12M | 9.01M | 0.51M |
| Other non cash items | 0.87M | -0.85070M | -2.53000M | 197.76M | 28.16M |
| Free cash flow | -10.32400M | -26.83500M | -31.81000M | -33.37500M | -16.76200M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| BRNHF Broncus Holding Corporation |
- -% | 0.08 | - | - | 242.11 | 0.20 | 0.52 | |
| ABT Abbott Laboratories |
-0.3402 0.38% | 88.07 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
-3.305 1.07% | 304.50 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.0699 0.09% | 79.27 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.96 2.12% | 44.33 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, and thoracic surgery staining location; and BroncTru, a disposable transbronchoscopic dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; BioStarNeedle, a single use ultrasound-guided needle for retrieval of tissue samples; and Steerable Sheath. The company was incorporated in 2012 and is headquartered in Hangzhou, China.
Building 8, Hangzhou, China
| Name | Title | Year Born |
|---|---|---|
| Mr. Guowei Zhan | CEO, GM & Exec. Director | 1976 |
| Mr. Hong Xu | CTO & Exec. Director | 1987 |
| Mr. Todd A. Cornell | Pres of Broncus Medical & Uptake Medical | 1970 |
| Thomas M. Keast | VP, Operation Director & Scientist in resident | NA |
| Feng Yao | Sr. Accountant | NA |
| Ms. Elaine Lu | Director of Fin. & Admin. | NA |
| Ms. Yin Kwan Ho | Company Sec. | 1977 |
| Mr. Hong Xu | Chairman of the Board & CEO | 1987 |
| Ms. Elaine Lu | Director of Finance & Administration | NA |
| Ms. Ka Yan Suen | Company Secretary | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.